Solving Cold Chain Issues for
Pharmaceutical Manufacturers

Cold Chain Challenges for Biopharmaceutical Manufacturers

As a large, global pharmaceutical company, you have deep domain expertise and extensive in-house capabilities across pharmaceutical drug discovery, development, and manufacturing. And you likely have a robust R&D pipeline with many drug candidates at various stages of development. As more of your drug candidates move beyond traditional pharmaceutical approaches—encompassing cell and gene therapies, monoclonal antibodies, and other biologics—even the most expansive in-house resources and expertise can be taxed.

A growing number of advanced biologic therapies have emerging cold chain regulatory requirements. But when it comes to designing and implementing a complex cold chain strategy, even the largest pharmaceutical manufacturers don’t always have the resources to devote to the task. With competitive pressures to get new therapies to market fast, prolonged timelines for traditional regulatory approval processes, and high failure rates in the clinic, you can’t afford costly delays due to cold chain regulatory obstacles.